

**Amendments to the Specification**

After the section entitled "CROSS-REFERENCE TO RELATED APPLICATIONS", delete the words "Not applicable.", and insert therefore the following paragraph on page 1, line 5:

-- This application is a U.S. National Phase application under 35 U.S.C. §371 of PCT Application No. PCT/US03/10740, filed April 8, 2003, which claims priority under 35 U.S.C. §119 from U.S. Provisional Application No. 60/372,234, filed April 12, 2002. --

After the last page, insert the paragraph:

**ABSTRACT OF THE DISCLOSURE**

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.